CTABF - Canntab Therapeutics Limited

Other OTC - Other OTC Delayed Price. Currency in USD
0.3696
0.0000 (0.00%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close0.3696
Open0.3696
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3696 - 0.3696
52 Week Range0.3028 - 0.6850
Volume1,500
Avg. Volume1,419
Market Cap9.242M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 07, 2016
1y Target EstN/A
  • Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status
    CNW Group

    Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status

    The final step to obtain a licence to process Canntab's cannabis hard pill formulation, at its fully built out Markham, Ontario facility. Retains Larry Latowsky , former CEO of Katz Group Canada and its flagship holding Rexall, as an advisor in order to strengthen Canntab's commercialization efforts. TORONTO , Dec. 23, 2019 /CNW/ - Canntab Therapeutics Limited (PILL.CN) (CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces today the submission of the Company's Site Evidence Package to Health Canada for approval of their Licence Producer Status (Processing-Standard, Federal Sales-Medical).

  • PR Newswire

    Canntab Achieves Key Milestone: Canntab Enters Into Supply & Distribution Agreements With Exactus for the Purchase of Hemp-derived CBD Oil and the Distribution of Canntab's Hard Pill Formulations in the United States

    - Canntab will manufacture its hard pill formulations (made from CBD and other hemp derivatives) in a Florida facility operated by Exactus, using equipment supplied by Canntab - Manufacturing is expected ...

  • GlobeNewswire

    Exactus, Inc. Enters into Supply & Distribution Agreement with Canntab Therapeutics to Produce Immediate and Extended Release Tablets

    Exactus, Inc. (EXDI) (the “Company”), an industrial hemp farm operator and manufacturer of hemp-derived phytocannabinoid products, today announced that it has entered into a supply and distribution agreement with Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) to produce immediate and extended release tablets. Exactus will provide Canntab a subleased space in their facility in Florida to equip for the purpose of manufacturing advanced hemp derived cannabinoid tablets.

  • PR Newswire

    Canntab Achieves Key Milestone: Canntab Enters Into Supply & Distribution Agreements With Exactus for the Purchase of Hemp-Derived CBD Oil and the Distribution of Canntab's Hard Pill Formulations in the United States

    Canntab will manufacture its hard pill formulations (made from CBD and other hemp derivatives) in a Florida facility operated by Exactus, using equipment supplied by Canntab Manufacturing is expected to ...

  • PR Newswire

    Canntab to utilize the advanced BOSS extraction system from Word Class Extractions to further its own extraction capabilities

    TORONTO, Oct. 8, 2019 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, today announced the signing of a binding Letter of Intent ("LOI") to establish a joint venture (the "Joint Venture") with World Class Extractions Inc. (CSE:PUMP) ("WCE"). Pursuant to the terms of the LOI, WCE will install certain extraction and processing systems (the "Systems") at Canntab's production facility in Markham, Ontario (the "Facility").

  • Newsfile

    InvestmentPitch Media Video Discusses Canntab's Receipt of Initial Indication of Patentability for Immediate Release Cannabidiol Formulation - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 16, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation. The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not only patentable but also ...

  • PR Newswire

    Canntab Receives Initial Indication of Patentability for Immediate Release Cannabidiol Formulation

    TORONTO, Aug. 15, 2019 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation (the "Immediate Release Formulation"). The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not only patentable but also novel, non-obvious and useful.

  • Newsfile

    InvestmentPitch Media Video Discusses Canntab's Update of Significant Developments Including Hemp Cultivation and Gel Capsule Manufacturing - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 1, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has updated investors about significant developments. Canntab, with headquarters and R & D located in Markham, currently operates out of Cobourg, Ontario where the company has co-location and profit sharing agreements with its strategic partner, FSD Pharma Inc. (CSE:HUGE), a holder of both ...

  • CNW Group

    Canntab provides corporate update

    Commercial batch manufacturing of oil-filled gel capsules to begin in Cobourg , leading to a Health Canada request for authorization to begin full scale production and sale. Construction nears completion in Markham , and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status. A pharmacist and drug formulation specialist has been hired to assist with our product applications to Health Canada.

  • ACCESSWIRE

    Marijuana Investor Magazine June/July 2019 Issue Now Available

    ATLANTA, GA / ACCESSWIRE / June 24, 2019 / CannaInvestor Magazine, the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced today ...

  • ACCESSWIRE

    Canntab Therapeutics Featured in the Canadian Cannabis Investor Magazine

    TORONTO, ON / ACCESSWIRE / June 24, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA:TBF1.F) (the " Company " or " Canntab "), the leading innovator in hard pill ...

  • Newsfile

    InvestmentPitch Media Video Discusses Canntab's Term Sheet with Heritage Cannabis to Process Hemp into High Quality CBD Oil for Canntab's Gelcaps - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - May 31, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has signed a term sheet with Heritage Cannabis Holdings. Under the Term Sheet, Canntab will provide hemp to Purefarma Solutions, a subsidiary of Heritage Cannabis Holdings, for the purpose of processing the hemp into high quality CBD oil. Canntab will transform the resulting oil ...

  • ACCESSWIRE

    Canntab Therapeutics to Present at the 9th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5th at 11:20AM PST / 2:20PM EST. Richard Goldstein, co-founder and Chief Executive Officer of Canntab Therapeutics will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges" stated Chris Lahiji, while waiting in the longest TSA line in history.

  • Business Wire

    Canntab Signs Term Sheet with Heritage for Processing Hemp for Sale of CBD Filled Gelcaps

    Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) ("Heritage") for the purpose of capsule manufacturing (the "Term Sheet"). Under the Term Sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions ("Purefarma") for the purpose of processing that hemp into high quality CBD oil.

  • PR Newswire

    Canntab signs term sheet with Heritage for processing hemp for sale of CBD filled gelcaps

    TORONTO, May 30, 2019 /PRNewswire/ - Canntab Therapeutics Limited (PILL.CN) (CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) ("Heritage") for the purpose of capsule manufacturing (the "Term Sheet"). Under the Term Sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions ("Purefarma") for the purpose of processing that hemp into high quality CBD oil.

  • Newsfile

    InvestmentPitch Media Video Discusses Canntab's Receipt of Cultivation Licence from Health Canada to Grow Industrial Hemp - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - May 22, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has received a cultivation licence from Health Canada to grow industrial hemp. Canntab intends to utilize the Hemp License to grow and cultivate its own supply of hemp biomass for the extraction of CBD and for the purpose of identifying high CBD strains ...

  • CNW Group

    Canntab Receives Cultivation Licence for Industrial Hemp

    Additionally, Canntab's application is currently "In Progress" to obtain a Cannabis Licence (Processing- Standard, Federal Sales - Medical) from Health Canada at its Markham, Ontario facility. TORONTO , May 21, 2019 /CNW/ - Canntab Therapeutics Limited (PILL.CN) (CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has received a cultivation licence for industrial hemp from Health Canada pursuant to the Cannabis Act ( Canada ) (the "Hemp Licence").

  • PR Newswire

    Canntab Therapeutics Now Trading on the OTCQX Best Market

    "Historically, it's been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX Best Market. "Ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about our advanced cannabinoid formulations that utilize our patent pending proprietary processes," says Jeff Renwick, co-founder and Chief Executive Officer of Canntab. Canntab is well positioned in the emerging medical cannabis market with 13 patents pending in the United States and Canada covering a range of proprietary processes and formulations.